

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 986 758 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**16.11.2005 Bulletin 2005/46**

(51) Int Cl.<sup>7</sup>: **G01N 33/567, G01N 33/487,  
C12Q 1/02, C12M 1/40**

(21) Application number: **98928750.3**

(86) International application number:  
**PCT/SE1998/001058**

(22) Date of filing: **03.06.1998**

(87) International publication number:  
**WO 1998/055870 (10.12.1998 Gazette 1998/49)**

**(54) DETECTION OF BIOLOGICALLY ACTIVE MOLECULES BY USE OF PRE-ACTIVATED  
CELL-BASED BIOSENSORS IN LIQUID-BASED SEPARATION SYSTEMS**

NACHWEIS BIOLOGISCH AKTIVER MOLEKÜLE DURCH VERWENDUNG VON  
VORAKTIVIERTEN ZELLGESTÜTZTEN BIOSENSOREN IN TRENNSYSTEMEN AUF  
FLÜSSIGKEITSGRUNDLAGE

DETECTION DE MOLECULES BIOLOGIQUEMENT ACTIVES A L'AIDE DE CAPTEURS  
BIOLOGIQUES PRE-ACTIVES A BASE DE CELLULE DANS DES SYSTEMES DE SEPARATION A  
BASE DE LIQUIDE

(84) Designated Contracting States:  
**DE GB**

(30) Priority: **04.06.1997 SE 9702112**

(43) Date of publication of application:  
**22.03.2000 Bulletin 2000/12**

(73) Proprietor: **CELLECTRICON AB**  
**412 96 Göteborg (SE)**

(72) Inventors:  
• **ORWAR, Owe**  
**S-411 37 Göteborg (SE)**  
• **JARDEMARK, Kent**  
**S-426 72 V Frölunda (SE)**

(74) Representative: **Adam, Holger et al**  
**Kraus & Weisert,**  
**Patent- und Rechtsanwälte,**  
**Thomas-Wimmer-Ring 15**  
**80539 München (DE)**

(56) References cited:  
**WO-A-90/04645 WO-A-93/24629**  
**WO-A-94/20841 WO-A-96/10170**  
**WO-A-96/13721 US-A- 4 906 779**  
**US-A- 5 114 681 US-A- 5 597 699**  
  
• **FARRE ET AL: 'Screening of ion channel  
receptor agonists using capillary  
electrophoresis-patch clamp detection with  
resensitized detector cells' ANAL CHEM vol. 73,  
2001, pages 1228 - 1233**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 0 986 758 B1**

## Description

### Field of the invention

[0001] The present invention relates to a method and an apparatus for detection of endogenous and synthetic receptor antagonists and receptor modulators, such as e.g. drugs and pharmaceutically active substances. More specifically, the present invention relates to a method and an apparatus based on the use of a miniaturised liquid-based separation technique coupled to a biosensor activated by a receptor agonist and thus giving rise to a measurable response that is affected in a measurable way by the receptor antagonist to be detected.

### Background of the invention

[0002] Biologically active compounds generally lack features enabling sensitive detection thereof by conventional techniques, and their roles in biochemical and physiological processes are therefore often difficult to elucidate.

[0003] The detection of biologically active compounds is of particular interest in the pharmaceutical field, e.g. during development of new drugs. Since many native and synthetic substrates constituting commercial drugs act as inhibitors of dysfunctional events in the human body, it is of importance to find systems that enable screening or detection of molecules with that mode of action.

[0004] In recent years, there has been an exponential increase in the number of compounds which are interesting for screening. Synthetic libraries from drug companies and natural products have been some of the sources of these compounds. The compounds origin from a broad spectrum of different organisms, such as bacteria, insects, plants and marine organisms. This, together with the introduction of combinatorial libraries for the manufacturing of several thousands of compounds have led to a great demand for new screening techniques which are faster and more selective than the ones used today. Known methods used for drug screening are generally based on pure chemical binding between compounds extracted from, for example, natural products and target molecules, such as receptors, enzymes or nucleic acids. The target molecules can also be included in biological systems, such as living cells, where the merits of chemical recognition and biological amplification are combined.

[0005] The use of specific target molecules for the evaluation of a compound's biological potential is based on the creation of systems of biological relevance for the analysed compound. Strategies in this field often include expression of cloned cDNA in different cell systems for the production of a functional target molecule in its natural environment.

[0006] There are also examples of screening systems

which are based on cell effects where the response cannot be traced to a single target molecule.

[0007] Several different techniques are presently used for biological screening and characterisation of potential drugs, and some examples of these techniques are given below.

[0008] *Microphysiometry*: During the growth of a typical biological cell, carbon-containing nutrients such as glucose are taken up and acidic metabolic products such as lactic acid are released. In microphysiometry these changes in metabolic rate are recorded as changes in the rate of acidification of the medium surrounding the cells (see e.g. Raley-Susman, K. M., et al., J. Neurosci. 12:773, 1992; Baxter, G. T., et al., Biochemistry 31:10950, 1992; Bouvier, C., et al., J. Recept. Res. 13: 559, 1993; and McConnell, H. M., et al., Science 257: 1906, 1992). Virtually any molecule that affects the cell can be detected by this method. Such molecules include neurotransmitters, growth factors, cytokines and so forth. The microphysiometry is unable to distinguish between different antagonists acting on the same receptor system and can therefore not be used for binary or more complex solutions of such agents. Other drawbacks of this system are the low-level detection, measuring changes in pH is far less selective than measuring responses on the receptor level, and slow recovery rates.

[0009] *Immunoassays*: This group of techniques is based on in vitro procedures for screening of specific antigens (see e.g. Tu, J., et al., Clin. Chem. 44:232, 1998; Pinilla, C., et al., Biomed. Pept. Proteins Nucleic Acids 1:199, 1995; Tawfik, D. S., et al., Proc. Natl. Acad. Sci. USA 90:373, 1993; and Houghten, R. A., et al., Biotechniques 13:412, 1992). Antibodies, often immobilised, are used as targets for antigens. The antigen-antibody interaction is detected by a second antibody, which is labelled by e.g. an radioactive isotope. The problems with these immuno-based techniques are related to the difficulties in raising specific antibodies for small molecules that are identical or resemble endogenous compounds. Another problem is related to the handling of radioactive substances.

[0010] *Use of combinatorial libraries*: Synthetic combinatorial libraries have proven to be a valuable source of diverse structures useful for large-scale biochemical screening (see e.g. Sastry, L., et al., Ciba Found Symp. 159:145, 1991; Huse, W., Ciba Found Symp. 159:91, 1991; Persson, M. A., et al., Proc. Natl. Acad. Sci. USA 88:2432, 1991; Kang, A. S., et al., Proc. Natl. Acad. Sci. USA 88:4363, 1991; Houghten, R. A., et al., Nature 354: 84, 1991; Clackson, T., et al, Nature 352:624, 1991; and Ostresh, J. M., et al., Proc. Natl. Acad. Sci. 91:11138, 1991). The libraries are generated by a combination of solution and solid-phase chemistries and are cleaved off the solid-support for screening. When mixtures of compounds are screened, however, the possibility exists that the most active compound will not be identified.

[0011] *Separation techniques coupled to mass spectrometry*: Separation techniques such as liquid chroma-

tography, gas chromatography and capillary electrophoresis coupled to mass spectrometry or tandem-mass spectrometry create analytical systems available for structure evaluation (see e.g. Hsieh, S., et al., Anal. Chem. 70:1847, 1998; Tretyakova, N. Y., et al., J. Mass. Spectrom. 33:363, 1998; Bonnicksen, R., et al., Zaccchia 6:371, 1970; Taylor, G. W., et al., Br. J. Clin. Pharmacol. 42:119, 1996; and McComb, M. E., et al., J. Chromatogr. A 800:1, 1998). Mass spectrometry gives information about the molecular weight of the analysed molecule. With refined and controlled fragmentation of large molecules it is also possible to extract information about the sequence.

**[0012]** *Enzyme assays using proteases:* Many proteases have become targets for drug discovery (see e.g. Carroll, C. D., et al., Adv. Exp. Med. Biol. 436:375, 1998; Ferry, G., et al., Mol. Divers. 2:135, 1997; and Jiracek, J., et al., J. Biol. Chem. 270:21701, 1995), from viral proteases required for the generation of active viral proteins to mammalian proteases that process pro-hormones to their active mature forms. Assays have been developed in bacterial systems to screen for compounds that inhibit protease activity. Most of these involve the co-expression of both the protease and a target reporter gene (the gene that encoded the protein which creates a measurable effect) in the same cell. A number of in vitro biochemical assays have also been developed. In most of these cases, a peptide containing the protease cleavage site is labelled at one end using either a radioactive or a fluorescent tag. The other end of the peptide molecule is adhered to a plate or a bead. In the presence of an active protease, the peptide is cleaved and the labelled end is released. The loss of signal from the labelled end of the peptide molecule after washing reflects the activity of the protease and can be easily monitored. For detection of protease inhibitor the grade of maintenance of the signal can instead be measured. These assays are, however, often time consuming since they involve genetic engineering.

**[0013]** A significant limitation of the above mentioned methods is the capacity; the number of compounds that can be rapidly evaluated is extremely low. Alternative methods for high through-put screens are needed.

**[0014]** Another major disadvantage of these known biological screening systems is that they involve extensive multistep purification and isolation of the compounds which are to be tested.

**[0015]** Capillary-based separation methods for identifying bioactive analytes in a mixture have earlier been described in WO 96/10170 (PCT/US95/12444). The methods described herein is however not fully satisfying for detection of antagonists. In the application detection of antagonists is mentioned. However, it seems that the agonist needed for detection of antagonists is then either included in the bathing solution or fed to the cell by a second capillary or tube system. A major drawback with this solution is that the agonist would immediately dissipate from the surface of the cell-based biosensor

when the separation process is started. This eliminates the effect of pre-activation which is necessary for accurate biosensor-detection of antagonists.

## 5 Summary of the invention

**[0016]** The disadvantages of the above mentioned methods for drug screening can be eliminated with the method according to the present invention.

10 **[0017]** The present invention provides methods and apparatus for detection of biologically active analytes separated by liquid-based separation means. The analytes or antagonists to be detected act can act as ligands, which mean that they can bind to a specific receptor or receptors. The method employs cell-based biosensors expressing specific receptors to serve as ligand detectors. An important feature of the invention is that the receptor, comprising the functional unit of the detector, is pre-activated by constantly including a receptor-specific agonist or modulator into the liquid-based separation means. Analytes, such as antagonists, is detected in that they modulate or inhibit the pre-activated receptor response. The use of a pre-activated or constantly activated biosensor is one of the most important characteristics of the present invention.

25 **[0018]** Thus, the present invention relates to a method for detection of at least one receptor antagonist and/or at least one receptor modulator, comprising the following steps:

- 30 (I) a sample containing the receptor modulator is fractionated by use of capillary electrophoresis means,
- (II) a fraction containing the receptor modulator is fed directly to a patched-clamped biosensor (9) which is activated by a receptor agonist and, as a result of this activation, is generating a measurable response, said agonist being fed to the biosensor through the capillary electrophoresis means together with the modulator, said activation of the biosensor (9) being pulsed by delivery of the receptor agonist to the biosensor for short period of times, said periods being separated by other periods when no agonist is delivered to the biosensor, and
- 35 (III) the change of the response resulting from deactivation of the receptor agonist-activated biosensor (9) by the receptor modulator is measured.

40 **[0019]** The present invention also relates to an apparatus for detection of a receptor antagonist comprising a capillary electrophoresis separation capillary containing an electrolyte supplemented with an appropriate receptor agonist, the sample inlet part of which is connected to a high-voltage power supply through a buffer vial containing a buffer supplemented with an appropriate receptor agonist and the grounded outlet part of which ends close to a patch-clamped biosensor that is activated by the receptor agonist and deactivated by the frac-

tionated antagonist; the apparatus further comprising a patch clamp electrode and means to record currents detected by the patch clamp electrode and a means for pulsed delivery of the receptor agonist to the biosensor.

[0020] The method and the apparatus according to the present invention enables a one-step fractionation immediately followed by detection. This is a big advantage compared to known techniques which involves several separation steps.

[0021] The present invention also relates to an apparatus and method for better resolution of the separated analytes or antagonists due to a periodic resensitisation of the biosensor by an interlocked pulsed flow system.

[0022] The methods and the apparatuses according to the invention have a variety of uses. For example, they are well-suited for drug screening since many drugs or pharmaceutically active components are receptor antagonists or receptor modulators, but they can also be used for applications in other areas such as environmental, food, and cosmetic industries.

[0023] When the method or the apparatus according to the invention is used for screening of antagonists or drugs they provide a number of advantages over methods according to prior art. Since cell biosensors of the type described herein by themselves are not particularly useful at identifying antagonists or drugs acting as inhibitors in a mixture of antagonists or drugs, it is a great advantage to use the method according to which they are pre-activated by a selective agonist which is incorporated into the running buffer in the liquid-based separation means. An advantage of this system is that the state of the biosensor, that is the degree of receptor activation, is known through this continuous activation by an agonist. Another significant advantage of the present invention is that long-time exposure of the cell by agonist or antagonist can be avoided by displacement of the cell from the outlet of the liquid-based separation means. This is in contrast to keeping the concentration of the agonist at a high level in the buffer solution in the Petri-dish, as described in the above mentioned patent application PCT/US95/12444. The fact that the agonist according to the present invention is present in the liquid-based separation means where the separation of the antagonist takes place provides a very important advantage compared to the methods described in WO 96/10170 since this results in a pre-activation of the biosensor enabling accurate detection of antagonists.

[0024] The characterising features of the invention will be evident from the following description and the appended claims.

#### Brief descriptions of the drawings

[0025] The invention will now be described in further detail hereinafter with reference to the accompanying drawings on which:

Fig. 1 A-C

shows, for comparison, absorbance detection, patch clamp detection and interlocked pulsed patch-clamp detection, coupled to capillary electrophoresis.

Fig 1 A shows the separation and detection of analyte 1 and analyte 2, with similar migration times, by absorbance detection in capillary electrophoresis. The recorded trace gives gaussian distributed and overlapping peaks.

Fig 1 B shows capillary electrophoresis-patch clamp detection of the same separation of analyte 1 and analyte 2, as in Fig. 1 A. Notable is that only analyte 1 is detected due to desensitisation.

Fig 1 C shows a theoretical prediction of that repeated resensitisation of the detector by interlocked pulsing gives an increased resolution in CE-PC detection of analyte 1 and analyte 2.

Fig. 2

shows a preferred embodiment of the apparatus according to the invention, namely a capillary electrophoresis-patch clamp detection system.

Fig. 3

A-B shows an enlarged part of the capillary electrophoresis-patch clamp detection system according to figure 2.

Fig 3 A shows the electrophoresis capillary. The capillary, into which a receptor antagonist has been injected, is filled with a receptor agonist-supplemented buffer and its flow is directed onto the surface of a patch-clamped cell.

Fig 3 B shows the same capillary and the same patch-clamped cell at a later point of time when the receptor antagonists have migrated through the entire length of the capillary and started to antagonise the binding of receptor agonists.

Fig. 4

A - B show a model of a device constructed for switching between superfusion and electrophoresis.

Fig. A shows the device consisting of two fused-silica capillaries which are mounted in parallel.

The cell, which is attached to the patch clamp electrode, is placed in front of one of the two capillaries by a micromanipulator.

Fig. 4 B illustrates how the receptors at the cell-surface are resensitised due to superfusion of the cell by a physiological buffer when the cell is in position one.

Fig. 4 C illustrates how electrophoretically separated analytes are detected by means of patch-clamp when the cell is in position two.

Fig. 5

A and B show a schematic drawing pre-

senting a second strategy for resensitisation of a receptor system used in patch clamp detection. This super-fusion system comprises a micropipette which is placed close to the cell in the vicinity of the electrophoresis capillary outlet. A buffer flow from the micropipette is applied leading to washing of the analytes from the surface of the patch-clamped cell. Dissociation of the analytes from the receptors makes the cell detector resensitised. When the buffer flow is interrupted the electrophoretically separated analytes are able to bind to the receptors at the cell surface and an ion-channel mediated current is recorded by the patch-clamp amplifier system.

Fig. 6 A-C shows electropherograms illustrating controls and detection of  $Mg^{2+}$  ions.

Fig. 6 A illustrates a control trace showing activation of NMDA receptors by NMDA and glycine,

Fig. 6 B illustrates a blocked response of the NMDA receptor-mediated current by separated  $Mg^{2+}$  ions.

Fig. 6 C shows a control-trace presenting the unaffected NMDA receptor response after injection of HEPES-saline containing NMDA and glycine.

Fig. 7 shows current-to-voltage relationships obtained during constant activation of the NMDA receptor and during the attenuation of this response by separated  $Mg^{2+}$  ions.

Fig. 8 shows an electropherogram illustrating patch clamp detection in capillary electrophoresis of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 6,7-dichloro-3-hydroxy-2-quinoxaline-carboxylic acid (DCQXC).

#### Detailed description of the invention

[0026] Below are definitions and explanations of several terms used in the description and in the appended claims.

[0027] The term "liquid-based separation means" refers to any method or apparatus for separation of a mixture of analytes or antagonists that are dissolved in a physiologically buffer, solution or any other liquid. Examples could be variations of capillary electrophoresis, such as capillary zone electrophoresis, capillary gel electrophoresis, micellar electrokinetic capillary electrophoresis, capillary isoelectric focusing, capillary isotachopheresis, and affinity capillary electrophoresis, as well as variations of micro liquid chromatography, such as open tube liquid chromatography.

[0028] The term "cell-based biosensor" refers to an

intact cell, a part of an intact cell (such as a membrane patch), or a cell in electrical communication with a patch-clamp glass-electrode or another material, a patch or piece of a cell-membrane which is in electrical communication with a solid material as, for example, a glass-capillary, plastic or silicon surface or anything related.

[0029] The term "target molecule" refers to a macromolecule composed of a protein, glycoconjugates or lipids, which interacts with or binds to a ligand, analyte, an antigen or anything related. A target molecule can be a receptor, an antibody, an enzyme, or anything related. The binding of an analyte, ligand or antigen may trigger a physiological relevant process which signals the ligand's or the analyte's biological activity. A target molecule may be associated to an artificial or a natural lipid mono- or bilayer membrane, such as a plasma membrane, mitochondrie membrane or golgi membrane.

[0030] The term "receptor" refers to a macromolecule capable of specifically interacting with a ligand molecule. Receptors may be associated with lipid bilayer membranes, such as the extracellular, golgi or nuclear membranes, and/or be present as free or associated molecules in the cell's cytoplasm. Further, receptors may be either native to the cell biosensor, i.e. normally expressed by the cell from which the cellbiosensor is derived, or recombinant, i.e. expressed in transfected cells or xenopus oocytes.

[0031] The term "ligand" refers to a molecule which binds to a receptor which either becomes activated or inactivated. Ligands can act on the receptor as agonists or antagonists or by modulating the response of the receptor by other agonists or antagonists. Binding of the ligand to the receptor is typically characterised by a high binding affinity.

[0032] As used in the description below and in the claims, the term "receptor antagonist" relates to receptor antagonists as well as to receptor modulators. Below, the term antagonist is used in the singular form, but the invention is of course also applicable to mixtures of different antagonists and/or receptor modulators.

[0033] To decrease the time needed for screening and to minimise the number of purification steps, screening of receptor antagonists and receptor modulators using biosensors, which include target molecules (i.e. receptors), is according to the present invention coupled, preferably on-line, to a miniaturised liquid-based separation technique. This combination of a separation technique and an on-line biosensor is based on a highly efficient one-at-a-time receptor antagonist delivery to the biosensor for functional detection.

[0034] The miniaturised liquid-based separation means used according to the present invention are suitable for separating ligand analytes in picolitre and nanolitre volumes. Preferably, the miniaturised liquid-based separation means used is capillary electrophoresis. The capillary electrophoresis can e.g. be any different mode of capillary electrophoresis known in the art,

such as capillary zone electrophoresis, CZE (see e.g. Jorgenson, J. W., Trends Anal. Chem. 3:51, 1984, and Altria, K., et al., Anal. Proc. 23:453, 1986), capillary gel electrophoresis, CGE (see e.g. Hjertén, S., et al., J. Chromatogr. 327:157, 1985; Hjertén, S., et al., Protides Biol. Fluids 33:537, 1985; Cohen, A. S., et al., Chromatographia 24:14, 1987; and Cohen, A. S., et al., J. Chromatogr. 397:409, 1987), micellar electrokinetic capillary electrochromatography, MECC (see e.g. Terabe, S., et al., Anal. Chem. 61:251, 1989, and Tsuda, T., et al., J. Chromatogr. 248:241, 1982), capillary electrochromatography, CEC (see e.g. Knox, J. H., Chromatographia 26:329, 1988, and Jorgenson, J. W., et al., J. High Resolut. Chromatogr. Chromatogr. Commun. 8:407, 1985), capillary isotachopheresis, CIPT (see e.g. Everaerts, F. M., et al., Isotachopheresis: Theory. Instrumentation, and Application, Elsevier, Amsterdam, 1976, and Bocek, P., et al., Anal. Isotachopheresis, VCH Verlagsgesellschaft, Weinheim, 1988), or affinity capillary electrophoresis, ACE (see e.g. Chu, Y-H, et al., J. Med. Chem. 35:2915, 1992; Avila, L. Z., et al., J. Med. Chem. 36:126, 1993; and Gomez, F. A., et al., Anal. Chem. 66:1785, 1994).

**[0035]** In its simplest and most common embodiment capillary electrophoresis is a miniaturised separation technique that fractionates chemical species on the basis of differences in their ratios of electrical charge-to-frictional drag in a solution. Since different molecules have different charge-to-frictional drag ratios, separated components migrate at characteristic rates, making identification possible. With capillary electrophoresis it is possible to separate complex chemical mixtures with high efficiency (up to  $10^6$  theoretical plates) in typically less than 20 minutes. Since capillary electrophoresis handles samples down to  $10^{-18}$  litre, it is well suited for micro- and nanotechnology applications.

**[0036]** In its simplest and most common embodiment, a capillary electrophoresis system consists of a narrow-bore (inner diameter 5-75  $\mu\text{m}$  fused-silica capillary (usually with a length of 20 to 100 cm) filled with an electrolyte solution. The ends of the capillary are placed in electrolyte-containing reservoirs having either a cathode or an anode connected to a high-voltage source. When an electrical field is applied across the solution-filled fused silica capillary, a layer of mobile charge that accumulates along the counter-charged fused silica surface induces electroosmosis (bulk solution flow). Under typical operating conditions for capillary electrophoresis this sheath of ions is positively charged, and consequently, drags bulk solution from the anode to the cathode. A practical result of electroosmosis flow is that during a separation in free-solution capillary electrophoresis, all species - whether possessing positive, neutral, or negative charge - can be made to migrate in the same direction past a single detector.

**[0037]** The biosensor used according to the present invention is preferably an eukaryotic or a prokaryotic cell containing specific receptors, a confluent layer of

such cells, a part of a cell membrane containing specific receptors or a cluster of cells containing specific receptors. It is also possible to use a detector based on receptors inserted into or on liposomes, lipid films or other materials as a plastic surface or any related material.

**[0038]** The cells used for the biosensor, including a target molecule or a recombinantly expressed target protein, preferably a receptor, can be human, bacterial and/or yeast cells. Mammalian tissue cultured cells such as Chinese hamster ovary (CHO) cells, NIH-3T3 and HEK-293 cells, for example, are especially advantageous as cell-based biosensors expressing recombinant target molecules, in that they provide an environment that is similar to the milieu of the natural human cells (see e.g. Beohar, N., et al., J. Biol. Chem. 273:9168, 1998; Park, K., et al., J. Membr. Biol. 163:87, 1998; and Hirst, R. A., et al., J. Neurochem. 70:2273, 1998). To a great degree permeability, post-translational processing, signalling and coupling to other cellular factors in these cells are similar to these processes in most mammalian cells.

**[0039]** Another cell-system frequently used for expression of recombinant proteins is yeast (see e.g. Li, Z., et al., Eur. J. Biochem. 252:391, 1998). Yeast cells offer a number of advantages; they are well characterised, they are easy to manipulate genetically and fast growing. It has also been shown that they contain the machinery for post-translational modification and they possess intracellular signalling systems.

**[0040]** Furthermore, Gurdon and colleagues (see Gurdon, J. B., et al., Nature 233:177, 1971) opened a broad spectrum of possibilities for the study of the function of proteins by demonstrating the ability of *Xenopus laevis* oocytes to synthesise exogenous proteins when injected with mRNA. The oocyte-model is a particularly attractive approach to the investigation of the structure-function relations of membrane proteins. Consequently, expression of functional receptors for neurotransmitters and ion-channels were demonstrated in oocytes in the beginning of the 1980s (see Sumikawa, K., et al., Nature, London 292:862, 1981, and Barnard, E. A., et al., Proc. R. Soc. London Ser. B 215:241, 1982).

**[0041]** Thus, living cells used as biosensors are particularly advantageous because of the physiological and functional information which can be extracted from a receptor-induced response.

**[0042]** As stated above, the present invention involves the use of receptor agonists making it possible to detect receptor antagonists. Nearly all cells possess on their surface a wide range of various receptors specific for appropriate agonists as well as antagonists. When binding a specific agonist, the receptor is activated and undergo a conformational change which triggers a cellular response.

**[0043]** These receptors have evolved their specificity during billions of years, which makes them very suitable as highly specific functional units in biosensors. Glutamate receptors, for example, play a crucial role in neuro-

transmission, the formation of neuronal circuits, in synaptogenesis and synaptic plasticity, including long-term potentiation (LTP) and long-term depression (LTD). Excessive activation of glutamate receptors is also thought to contribute to the neurodegeneration which takes place in a wide range of neurological insults such as brain ischemia (see e.g. Beneviste, H., et al., *J. Neurochem.* 43:1369, 1984, and Hagberg, H., et al., *J. Cereb. Blood Flow Metab.* 5:413, 1985) and epilepsy (see e.g. Aram, J. A., et al., *J. Pharmacol. Exp. Ther.* 248:320, 1989; Yeh, G. C., et al., *Proc. Natl. Acad. Sci USA* 86: 8157, 1989; and Hosford, D. A., et al., *Soc. Neurosci. Abstr.* 15:1163, 1989).

[0044] The roles of glutamate receptors are strongly coupled to their ion-permeability properties, both in the normal and dysfunctional brain. Their selective permeability to  $\text{Na}^+$ ,  $\text{K}^+$  and  $\text{Ca}^{2+}$ , makes them mediators of synaptic transmission in many neurons of the central nervous system (CNS). A key event in glutamate induced cell death, for example, is increased intracellular  $\text{Ca}^{2+}$  which generates free radicals and endonucleases (see e.g. Siesjö, B. K., et al., *J. Cereb. Blood Flow Metab.* 9:127, 1989, and Coyle, J. T., et al., *Science* 262: 689, 1993) as well as transcriptional activation of specific "cell death". Thus naturally expressed receptors, as for example glutamate receptors, constitute excellent and selective detectors for detection and discovering of endogenous drug candidates, which may modulate or inhibit a wide range of receptor systems involved in the development of various diseases.

[0045] Bacteria such as *Escherichia coli*, *Bacillus* sp. and *Staphylococcus aureus* as well as yeast such as *Saccharomyces cerevisiae* provide alternative expression systems for cloned recombinant mammalian genes as well as microbial targets. Bacteria are genetically well characterised, have a short generation time, are easy to manipulate and inexpensive to grow. Thus these amplification systems provides a means of producing sufficient material of cDNA expressing a specific protein, which can be used in production of mRNA for injection in *Xenopus* oocytes or for transfection into mammalian tissue cultured cells.

[0046] The advantage with expressing recombinant genes in a cell-based biosensor used according to the invention is that the receptors in any of the cell- or cell membrane-based biosensors can be of any kind, e.g. ligand-gated ion channels, metabotropic, hematopoietic, tyrosine-kinase-coupled etc. Biosensors, expressing recombinant receptors, can also be designed to be sensitive to drugs which may inhibit or modulate the development of a disease. This sensitivity of the biosensor will be governed by the role of a specific recombinant receptor in disease development. Thus, the choice of the biosensor is based on the receptor antagonist one wishes to screen. For example, it is possible to use liver cells in order to study receptor antagonists used in pharmaceuticals meant to affect the liver.

[0047] Since the receptor antagonist to be detected

binds to the biosensor, e.g. containing cell receptors, without eliciting a response, the biosensor system needs to be activated, preferably constantly and preferably by a receptor agonist, in order to enable detection.

The activation caused by the receptor agonist is changed, normally decreased, by the receptor antagonist and this change of the response is detectable.

[0048] As stated above, the biosensor is either pre-activated or constantly activated by use of a receptor agonist. This receptor agonist is preferably included in the buffer solution in the liquid-based separation means.

[0049] The detection of the response generated by the activated biosensor and of the change of the response caused by the receptor antagonist to be detected are made by an appropriate technique depending on the type of the generated response. The response can e.g. be a transmembrane current measured by patch clamp or two-electrode voltage clamp, it can be fluorescence from voltage-sensitive dyes or it can be fluorescence from calcium-chelated fluorophores, such as Fura and Fluo-3 ( $\text{Ca}^{2+}$  chelating dyes), which are included in measurements of intracellular calcium coupled to activation of metabotropic receptors in the cell membrane. The preferred detection technique according to the invention is patch clamp detection, and the generated response measurable is thus an electrical current.

[0050] Katz and Thesleff discovered that the macroscopic endplate conductance falls within a few seconds when acetylcholine (ACh) is added to an endplate (see Katz, B., and Thesleff, S., *J. Physiol., London*, 138:63, 1957). This process is called desensitisation. Desensitised channels were unresponsive to added ACh and recover their sensitivity only some seconds or even minutes after the removal of ACh. Generally, a broad range ligand-receptor interactions at cell surfaces, which triggers cell responses with varying characteristics, i.e. increased conductance across the cell membrane, activation of G-protein coupled intracellular cascade processes, phosphorylation of proteins or triggering of intracellular modulations of transcription, desensitise. Such receptor properties may cause problems in detecting antagonists with similar electrophoretic migration times when biological samples are separated and detected by the CE-PC technique, where the receptor systems comprises the functional unit in the detector.

[0051] If two analytes (analyte 1 and analyte 2), as for example glutamate and aspartate, with similar migration times are separated and detected by a conventional detector such as an absorbance detector, the recorded trace will give gaussian distributed and overlapping peaks, as illustrated in figure 1 A where the separation and detection of analyte 1 and analyte 2, with similar migration times, by absorbance detection in capillary electrophoresis is shown. Even if the responses are improperly resolved, the trace gives information about two existing compounds in the sample. However, if the same sample is separated by the CE-PC technique, analyte 2 will not be detected when both analytes activate the

same desensitising receptor system. The receptor population will be activated and desensitised by analyte 1 before analyte 2 reaches the receptor surface leading to a single response in the electropherogram, as illustrated in figure 1 B, where capillary electrophoresis-patch clamp detection of the same separation of analyte 1 and analyte 2 as in figure 1 A is shown. Notable is that just analyte 1 is detected due to desensitisation. A solution to this problem involves pulsed resensitisation of the environment surrounding the cell-based detector. This will reactivate the receptors at a specific frequency due to repeated dissociation of the eluting analytes from the binding site of the receptor. The reactivation of the receptor population enables the analytes to repeatedly give desensitised responses which will be presented with a gaussian distribution, as illustrated in figure 1 C., where a theoretical prediction of that repeated resensitisation of the detector by interlocked pulsing gives an increased resolution in CE-PC detection of analyte 1 and analyte 2 is shown. This will also improve the quantitative abilities of the technique.

[0052] Below, preferred embodiments of the present invention will be described.

[0053] According to the first preferred embodiment the miniaturised separation technique is capillary electrophoresis and the biosensor is a patch-clamped cell or part of a cell membrane, and the detection means are thus a patch clamp electrode.

[0054] According to the patch clamp technique, a cell or part of a cell is firmly attached by suction to the tip of a glass micropipette, or a patch clamp electrode, and manipulated to yield one of several desired configurations, i.e., outside-out, inside-out, or whole-cell recording modes. The outside-out and inside-out configurations refer to the word "patch", that is a small piece of a cell membrane which is attached to the tip of an electrode for recording of single ion-channel currents (see e.g. Hamill, O. P., et al., Pflug. Arch. 391:85, 1981).

[0055] The patch clamp technique utilises in its simplest embodiment a highly sensitive feedback current-to-voltage converter, which has the ability to measure sub-pico-ampere currents. The measuring principle of patch clamp relies on the fact that the ionic flow across a cell membrane can be measured as an electrical current if the membrane potential is held constant, typically for neuronal cells in the range -30 to -90 mV.

[0056] There are three main reasons to use the patch clamp technique to measure small currents crossing the cell-membrane:

- (1) Clamping the voltage eliminates the capacitive current, except for a brief time following a step to a new voltage.
- (2) Except for the brief charging time, the currents that flow are proportional only to the membrane conductance, i.e. to the number of open ion-channels.
- (3) If ion-channel gating is determined by the trans-

membrane voltage alone, voltage clamp offers control over the key variable that determines the opening and closing of ion channels.

[0057] A preferred embodiment of the apparatus according to the present invention is shown in figure 2. The inlet end, i.e. the sample injection end, of a fused silica capillary electrophoresis separation capillary 1 is connected to a high-voltage power supply 2, preferably a positive high-voltage power supply, through a buffer vial 3. The buffer vial 3 is preferably housed in a polycarbonate holder equipped with a safety interlock to prevent electric shock. The capillary is grounded, e.g. approximately 5 cm above the outlet 4. The grounding can be accomplished by use of another buffer vial 5. The outlet 4 of the capillary 1 is positioned in a cell bath 6. The cell bath 6 contains the same media as the one used as electrolyte in the capillary electrophoresis capillary 1 with one exception - the media in the electrophoresis capillary 1 also comprises agonists which is lacking in the media in the cell bath. The same media as used in the cell bath is also used in the inlet buffer vial 3 and in the buffer vial 5. The use of only one media enables avoiding liquid junction potentials. The tip 7 of the patch clamp electrode 8 holding the patch-clamped cell 9 is preferably positioned approximately 5 - 25  $\mu\text{m}$  from the capillary outlet 4 by means of at least one micropositioner 10, 11 controlling the capillary and/or the patch clamp electrode. According to one embodiment, the whole system is placed in a Faraday cage (not shown). The patch clamp electrode is connected to a I-V-converter 12. In order to facilitate positioning of the capillary and the patch clamp electrode holding the cell, the cell bath is preferably placed on a microscope objective 13.

[0058] The function of the biosensor, in this case a patch-clamped cell, is illustrated in figure 3 A and 3 B.

[0059] The capillary electrophoresis capillary 1 in figure 3 A is filled with a receptor agonist-supplemented buffer with its flow directed onto the surface of a patch-clamped cell 9. The receptor agonists, shown in figure 3 A and 3 B as unfilled stars, continuously activate the ligand-gated ion channels 19 in the cell membrane 20 which, in this case, are permeable to sodium ions. Thus, when the receptor agonists bind to the receptors the sodium channels open and sodium ions diffuse from the outside of the cell into the cytoplasm. This flux of ions can be measured with the patch clamp electrode 8, preferably an Ag/AgCl-electrode, connected to a patch clamp amplifier, as an inward current, provided that the cell membrane is kept at a constant potential. In the capillary 1 there are also receptor antagonists, shown in figure 3 A and 3 B as filled tailed stars, i.e. the compound that are to be screened, which have been injected into the capillary 1 and have migrated a distance proportional to the charge-to-friction drag ratio of the receptor antagonist and the applied field strength.

[0060] In figure 3 B the receptor antagonists have migrated through the entire length of the capillary electro-



phoresis capillary 1 and started to antagonise the binding of receptor agonists. When the receptor antagonists bind to the receptors, the sodium permeable ion channel close and the inward transmembrane currents decrease. This decreased current is detected with the patch clamp electrode 8.

[0061] According to this preferred embodiment of the invention the receptors in the cell membrane are constantly activated by bathing of the cells in a solution containing specific receptor agonists. Preferably the separation technique used, in this case capillary electrophoresis, both deliver the receptor agonists and fractionates the receptor antagonists.

[0062] Thus, this preferred embodiment of the invention can be used for detection of any natural and synthetic receptor antagonists or receptor modulators that inhibit or negatively modulate receptor/ion-channel functions and effectively decrease receptor agonist-evoked membrane currents. This preferred embodiment of the invention thus offers possibilities to identify endogenous and synthetic receptor antagonists and to determine their mode of action on any ionotropic receptor system.

[0063] Another advantage of this preferred embodiment of the invention is that when ionotropic receptors are used in the capillary electrophoresis-patch clamp system, it is possible to gain full recovery of the detection system in milliseconds after the bioactive molecule has been washed away from the cell.

[0064] Another preferred embodiment of the present invention relates to re-activation of desensitising detector systems coupled to interlocked-pulsed superfusion, i.e. interlocked superfusion of the desensitised biosensor is used to resensitise the biosensor. This can be performed by pulsing the activation of the biosensor by delivery of the receptor agonist to the biosensor for short period of times, said periods being separated by other periods when no agonist is delivered to the biosensor, which is further described below.

[0065] According to the present invention it is thus possible to improve the resolution of the detected bioactive analytes by using a method or apparatus according to which a pulsed flow of a buffer solution washes an area around the biosensor constituting the detector which is coupled to a separation system. Practically, this can be performed in two ways, as illustrated in figures 4 A - C, and figure 5, respectively.

[0066] The strategy illustrated in figures 4 A - C involves two capillaries. One of the capillaries, capillary 1, is used for electrophoretic separations and for delivery of the agonist to the biosensor, and the other capillary 14 is used for delivery of buffer, for rinsing of the biosensor, in front of the capillary outlet. A means 15 fixes the capillaries 1, 14 parallelly together. The position of the capillaries fixed together is controlled by a micromanipulator 10. In this system a switching mode places the patch-clamped cell 9 either at the outlet of the capillary 14 coupled to the superfusion system 16 -

position one - or at the outlet of the electrophoresis capillary 1 - position two, as illustrated in figures 4 B and 4 C. In figure 4 B the situation when the cell is placed in position one is illustrated. In this position the receptors at the cell-surface are resensitised due to superfusion of the cell by a physiological compatible buffer when the cell is position one. In figure 4 C the situation when the cell is placed in position two is illustrated. In this position the electrophoretically separated analytes are detected by means of patch-clamp. Thus by shifting the capillaries at a specific frequency a train of desensitised responses is attained, an example of which is illustrated in figure 1 C.

[0067] A second strategy is illustrated in figures 5 A and 5 B. This set up involves a superfusion system comprising a glass micropipette 17 which is placed close to the cell 9 in the vicinity of the capillary outlet 4. The buffer flow applied from the glass-micropipette 17 leads to washing of the analytes from the surface of the patch-clamped cell 9, as shown in figure 5 A. The dissociation of the analytes from the receptors makes the cell detector resensitised. When the buffer flow is interrupted, as shown in figure 5 B, the electrophoretically separated analytes are able to bind to the receptors at the cell surface and an ion-channel mediated current is recorded by the patch-clamp amplifier system. The buffer flow from the pipette 17 is pulsed at a specific frequency by a external device (not shown in the figure) thereby re-activating the receptors for detection. The pulsing device can be any appropriate device known to persons skilled in the art (see e.g. Smart, T. G., J. Physiol. 447 : 587, 1992).

#### Examples

[0068] These examples are intended to further illustrate the invention.

[0069] In the examples below the following materials and methods were used.

[0070] *Biosensor-compatible buffers:* Separation of mixtures of glutamate receptor antagonists were performed using cell-based biosensor-compatible buffers. A cell-based biosensor-compatible buffer is a buffer which effectively keeps the cell-based biosensor in a functional and viable condition during the course of the experiment or the analysis procedure.

[0071] A slightly modified standard HEPES-saline buffer containing 140 mM NaCl, 5 mM KCl, 1 mM  $MgCl_2$ , 1 mM  $CaCl_2$ , 10 mM glucose and 10 mM HEPES (pH 7.4, NaOH) was used as extracellular and capillary buffer in examples 1 and 2 except in the separation of  $Mg^{2+}$  where  $MgCl_2$  were omitted. As described in the examples, the preferred agonist were only included in the capillary solution.

[0072] *Acute isolation of neurons from the olfactory bulb of the rat:* The cells used were interneurons from rat olfactory bulb acutely isolated according to the procedures described by Jacobson et al. (see Jacobson, I.,

Neurosci. Res. Comm. 8:11, 1991, and Jacobson, I., et al., Neurosci. Res. Comm. 10:177, 1992).

[0073] Newborn or adult rats (10-200 g) were anaesthetised with halothane (ISC Chemicals Ltd., Avonmouth, England) and decapitated. The olfactory bulbs were dissected and sliced into four pieces and placed in an incubation chamber. The chamber contained proteases from *Aspergillus oryzae* (2.5 mg/ml) which were dissolved in pre-warmed (32°C) HEPES-saline buffer (see above). After 25-30 min., the slices were washed with the same buffer solution for 20 min. The solutions were constantly perfused with 95% O<sub>2</sub> and 5% CO<sub>2</sub> during both the enzymatic treatment and the washing. The slices were then kept at 20°C in a HEPES-saline buffer containing 1 mM CaCl<sub>2</sub>, and bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. The slices were then disintegrated by shear forces by gentle suction through the tip of a firepolished Pasteur pipette. The cell suspension was then placed in a Petri dish and diluted with a Ca<sup>2+</sup>-containing (1 mM) HEPES-saline buffer. The Petri dish was transferred to the microscope stage. Viable interneurons were harvested up to six hours after the interruption of the enzymatic treatment. Chemicals and enzymes were obtained from Sigma (St Louis, MO, USA).

[0074] *Capillary electrophoresis*: The capillary electrophoresis separations were performed in fused silica capillaries (length: 25-50 cm, inner diameter: 50 µm) from Polymicro Tech., Phoenix, AZ, USA. The electrophoresis was performed by applying a positive potential of 12 kV to the inlet of the capillary by a high voltage supply, manufactured by LKB, Bromma, Sweden. Since the high voltages produce electrical field strengths of several hundred volts per centimetre, the outlet of the capillary was fractured and grounded 5 cm above the outlet to create an almost field free region at the position of the cell detector. The injections were made hydrodynamically by placing the capillary inlet in sample solution 20 cm above the outlet end for 10 sec.

[0075] *Patch-clamp detection*: The patch clamp detection was performed in the whole-cell configuration as described by Hamill, et al. (see Hamill, O. P., et al, Pflug. Arch. 391:85, 1981). The tip of the patch clamp electrode was placed 5-25 µm from the centre of the capillary outlet. Patch pipettes were fabricated from thick-walled borosilicate glass (code no GC150-10, Clark Electromedical Instruments, Pangbourne, Reading, UK). The diameters and the resistances of the tips were about 2-5 µm and 5-15 MΩ, respectively. The estimated series resistance was always less than 50 MΩ. The experiments were performed at room temperature of 18-22°C. The electrodes (reference and patch electrodes), contained a solution of 100 mM KF, 2 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 11 mM EGTA, 10 mM HEPES; the pH was adjusted to 7.2 with KOH.

[0076] The signals were recorded with a patch clamp amplifier (Model List L/M EPC-7, List-Electronic, Darmstadt, Germany), digitised (20 kHz, PCM 2 A/D VCR adapter, Medical Systems Corp., NY, USA), and stored

on videotape. For the production of electropherograms the signals from the videotape were digitised at 2 Hz.

[0077] It is of outmost importance to sample the signals at proper rates for gaining complete information.

5 [0078] For spectral analysis of whole-cell currents (see Colquhoun, D., et al., Proc. R. Soc. Lond. B. Biol. Sci. 199:231, 1981) the signal from the videoadaptor was filtered with an 8 pole Butterworth filter (bandwidth 3 kHz) and digitised at 6 Hz. Records were divided into 10 0.7 s blocks prior to calculation of the spectral density and the mean power spectrum was calculated by averaging all power spectra obtained from these blocks (at least 20). The receptor agonist-induced power spectra were subtracted from power spectra obtained during 15 membrane resting conditions. The resulting power spectra were fitted by a double Lorentzian function using a least-squares Levenberg-Marquardt algorithm with proportional weighting.

[0079] The relationships between the current and the 20 voltage (I-V) were obtained from current responses evoked by continuous perfusion of receptor agonist, and from blocked responses activated by electrophoretically separated receptor antagonists. The holding potential was changed by using a voltage ramp (-80 to +40 mV, duration 3 to 7 s, pClamp software, Axon Instruments; Foster City, CA, USA). For elimination of responses evoked by voltage-dependent ion channels, the I-V curve obtained between the responses were subtracted 25 from the ramp obtained during the receptor agonist- or receptor antagonist-activated responses.

#### Example 1 - separation and detection of Mg<sup>2+</sup>

[0080] In this example Mg<sup>2+</sup> ions, that reversibly block 35 the N-methyl-D-aspartate receptor in a voltage-dependent manner, were separated and detected by the patch-clamped cells.

[0081] The N-methyl-D-aspartate receptors on the cells were activated by N-methyl-D-aspartate (agonist) 40 and glycine (co-agonist), continuously delivered from the electrophoresis capillary.

[0082] The electrolyte in the capillary electrophoresis capillary and in the inlet vial used in this example was a Mg<sup>2+</sup>-free HEPES-saline containing 200 µM N-methyl-D-aspartate (NMDA) and 20 µM glycine. The same buffer 45 was used in the cell bath, but without NMDA and glycine.

[0083] In figure 6 A there is a control trace showing activation of NMDA receptors by NMDA (200 µM) and glycine (20 µM), delivered to the cell through the capillary electrophoresis capillary. The response occurs immediately following the start of the electrophoresis. 50

[0084] Mg<sup>2+</sup> ions (2 mM) hydrodynamically injected into the electrophoresis capillary migrate through the capillary in less than a minute and are detected as a 55 transient Gaussian-distributed attenuation of N-methyl-D-aspartate-activated current responses at a holding potential of -70 mV.

[0085] This is illustrated in figure 6 B by an electropherogram showing a blocked response of the NMDA receptor mediated current by separated  $Mg^{2+}$  ions migrating at approximately 20 s. The response is fitted to a Gaussian function.

[0086] In figure 6 C there is a control trace presenting the unaffected NMDA receptor response after injection of HEPES-saline containing 200  $\mu M$  NMDA and 20  $\mu M$  glycine.

[0087] The current-to-voltage relationships obtained during constant activation of the NMDA receptor and during the attenuation of this response by separated  $Mg^{2+}$  ions are shown in figure 6. The relationships display the characteristic features, i.e. blockade of inward currents at membrane resting potentials and unaltered outward currents at positive potentials. The current-to-voltage relationship for the NMDA receptor by activation of NMDA in  $Mg^{2+}$ -free media is represented by open squares, and in  $Mg^{2+}$ -containing media by filled diamonds. The plot in figure 7 is based on averages of three normalised current amplitudes at each decade (from -80 mV to +40 mV).

Example 2 - separation and detection of 6-cyano-7-nitro-quinoxaline-2,3-dione and 6,7-dichloro-3-hydroxy-2-quinoxaline-carboxylic acid

[0088] Since glutamate receptors are implicated in a wide range of diseases in the central nervous system (CNS) of mammals, including Alzheimer's disease and Parkinson's disease, and CNS dysfunctional processes such as epilepsy and neuronal death due to mechanical trauma and stroke, 6-cyano-7-nitroquinoxaline-2,3-dione and its analogues can be useful as drugs protecting against such diseases and disorders (see Honore, T., *et al.*, *Science* 241: 701 (1988)).

[0089] 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 6,7-dichloro-3-hydroxy-2-quinoxaline-carboxylic acid (DCQXC), both which reversibly block  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and kainate (KA) receptors, belonging to the glutamate receptor superfamily, were separated by capillary electrophoresis and detected on-line by patch-clamped cells.

[0090] The electrolyte in the capillary electrophoresis capillary, the medium in the cell bath and the buffer used in this example are the same as used in example 1, with the exception that the agonist in this example was kainate instead of NMDA and glycine.

[0091] Non-desensitising AMPA receptors were activated by 100  $\mu M$  KA (agonist) continuously delivered from the electrophoresis capillary.

[0092] At a holding potential of -70 mV CNQX and DCQXC were detected at characteristic migration times as transient attenuations of KA-activated current responses. This is shown in figure 8.

## Claims

1. A method for detection of a receptor modulator, characterised in that it comprises the following steps:

(I) a sample containing the receptor modulator is fractionated by use of capillary electrophoresis means,

(II) a fraction containing the receptor modulator is fed directly to a patched-clamped biosensor (9) which is activated by a receptor agonist and, as a result of this activation, is generating a measurable response, said agonist being fed to the biosensor through the capillary electrophoresis means together with the modulator, said activation of the biosensor (9) being pulsed by delivery of the receptor agonist to the biosensor for short period of times, said periods being separated by other periods when no agonist is delivered to the biosensor, and

(III) the change of the response resulting from deactivation of the receptor agonist-activated biosensor (9) by the receptor modulator is measured.

2. A method according to claim 1, wherein the response generated from the biosensor (9) is measured during the periods when no agonist is delivered to the biosensor.

3. A method according to claim 1 or 2, wherein the desensitised biosensor is resensitised by superfusion of the biosensor by delivery of buffer for rinsing of the biosensor.

4. A method according to claim 3, wherein the superfusion is performed by use of a column, placed in parallel to the capillary electrophoresis means.

5. A method according to claim 3, wherein the superfusion is performed by use of a glass pipette placed with its outlet adjacent to the outlet of the capillary electrophoresis means.

6. A method according to any one of claims 1-5, wherein the response generated by the biosensor (9) is an electrical current.

7. A method according to any one of claims 1-5, wherein the response generated by the biosensor (9) is fluorescence.

8. A method according to any one of the claims 1-7, wherein the biosensor (9) is constituted by at least one cell or part of a cell comprising at least one receptor for the agonist used and for the modulator to be detected.

9. A method according to any one of the claims 1-8, wherein the modulator to be detected is a substance affecting ligand-gated ion channels.
10. An apparatus for detection of a receptor modulator comprising a capillary electrophoresis separation capillary (1) containing an electrolyte supplemented with a receptor agonist, the sample inlet part of which is connected to a high-voltage power supply (2) through a buffer vial (3) containing a buffer supplemented with a receptor agonist and the grounded outlet part (4) of which ends close to a patch-clamped biosensor (9) that is activated by the receptor agonist and deactivated by the fractionated modulator; the apparatus further comprising a patch clamp electrode (8) and means to record currents detected by the patch clamp electrode and a means pulsed delivery of the receptor agonist to the biosensor.
11. An apparatus according to claim 10 wherein the capillary electrophoresis capillary (1) is a fused silica capillary.
12. An apparatus according to claim 10 or 11 further comprising at least one micropositioner (10) connected to the capillary and/or the patch clamp electrode.
13. An apparatus according to any one of the claims 10-12, wherein the patch-clamped biosensor (9) is placed in a cell bath (6).
14. An apparatus according to claim 13, wherein the electrolyte, the buffer and the cell bath are constituted of the same medium, with the only difference that the electrolyte and the buffer but not the cell bath are supplemented with an agonist.
15. An apparatus according to any one of the claims 10-14 further comprising a second capillary (14) for delivery of a buffer not comprising any agonist, said second capillary (14) being connected to a superfusion system (16), said apparatus also comprising means (10) for switching the position of the capillaries so that the patch-clamped biosensor (9) alternatively is placed in front of the outlet of the first capillary (1) and in front of the outlet of the second capillary (14).
16. An apparatus according to any one of the claims 10-14 further comprising means (17) for superfusing the patch-clamped biosensor (9) with a buffer not comprising any agonist.
17. An apparatus according to claim 16 further comprising means for pulsing the flow of the buffer delivered from the superfusion means.

18. A method according to claim 17, wherein said means (17) is a micropipette.

19. An apparatus according to any one of the claims 10-18, wherein the biosensor (9) is constituted of at least one cell or part of a cell comprising receptors for the modulator to be detected.

## 10 Patentansprüche

1. Verfahren zur Detektion eines Rezeptormodulators, **dadurch gekennzeichnet**, dass es die folgenden Stufen umfasst:

(I) eine Probe, die den Rezeptormodulator enthält, wird durch Verwendung eines Kapillarelektrophorese-Mittels fraktioniert;

(II) eine Fraktion, die den Rezeptormodulator enthält, wird direkt zu einem "patched-clamped"-Biosensor (9) geführt, der durch einen Rezeptoragonisten aktiviert wird, und als Resultat dieser Aktivierung wird eine messbare Antwort erzeugt, wobei der Agonist zusammen mit dem Modulator durch das Kapillarelektrophorese-Mittel zu dem Biosensor geführt wird, wobei die Aktivierung des Biosensors (9) durch Abgabe des Rezeptoragonisten an den Biosensor für kurze Zeitperioden gepulst ist, wobei die Perioden durch andere Perioden getrennt sind, wenn kein Agonist an den Biosensor abgegeben wird, und

(III) die Änderung der Antwort, die aus einer Desaktivierung des Rezeptoragonist-aktivierten Biosensors (9) durch den Rezeptormodulator resultiert, wird gemessen.

2. Verfahren nach Anspruch 1, wobei die vom Biosensor (9) erzeugte Antwort während der Zeitperioden gemessen wird, während der kein Agonist an den Biosensor abgegeben wird.

3. Verfahren nach Anspruch 1 oder 2, wobei der desensibilisierte Biosensor durch Superfusion des Biosensors durch Abgabe von Puffing zum Spülen des Biosensors resensibilisiert wird.

4. Verfahren nach Anspruch 3, wobei die Superfusion durch Verwendung einer Säule, die parallel zum Kapillarelektrophorese-Mittel angeordnet ist, durchgeführt wird.

5. Verfahren nach Anspruch 3, wobei die Superfusion durch Verwendung einer Glaspipette, die mit ihrer Auslassöffnung angrenzend an der Auslassöffnung des Kapillarelektrophorese-Mittels platziert ist, durchgeführt wird.

6. Verfahren nach einem der Ansprüche 1 bis 5, wobei die durch den Biosensor (9) erzeugte Antwort ein elektrischer Strom ist.
7. Verfahren nach einem der Ansprüche 1 bis 5, wobei die durch den Biosensor (9) erzeugte Antwort Fluoreszenz ist.
8. Verfahren nach einem der Ansprüche 1 bis 7, wobei der Biosensor (9) aus wenigstens einer Zelle oder einem Teil einer Zelle besteht, umfassend wenigstens einen Rezeptor für den verwendeten Agonisten und den zu detektierenden Modulator.
9. Verfahren nach einem der Ansprüche 1 bis 8, wobei der zu detektierende Modulator eine Substanz ist, die Ligandengesteuerte Ionenkanäle beeinflusst.
10. Apparatur zur Detektion eines Rezeptormodulators, umfassend eine Kapillarelektrophorese-Trennkapillare (1), die einen Elektrolyten, supplementiert mit einem Rezeptoragonisten, enthält, deren Probeneinlassteil an eine Hochspannungs-Stromversorgung (2) durch eine Pufferphiole (3), die einen Puffer supplementiert mit einem Rezeptoragonisten enthält, angeschlossen ist und deren abgesetztes Auslassteil (4) nahe an dem "patch-clamped"-Biosensor (9) endet, welcher durch den Rezeptoragonisten aktiviert und durch den fraktionierten Modulator deaktiviert wird; wobei die Apparatur außerdem eine "patch-clamp"-Elektrode (8) und Mittel zum Aufzeichnen von durch die "patch-clamp"-Elektrode detektierte Ströme und ein Mittel zur gepulsten Abgabe des Rezeptoragonisten zu dem Biosensor umfasst.
11. Apparatur nach Anspruch 10, wobei die Kapillarelektrophorese-Kapillare (1) eine Kapillare aus Quarzglas ist.
12. Apparatur nach Anspruch 10 oder 11, die außerdem wenigstens einen Mikropositionierer (10) aufweist, der mit der Kapillare und/oder der "patch-clamp"-Elektrode verbunden ist.
13. Apparatur nach einem der Ansprüche 10 bis 12, wobei der "patch-clamped"-Biosensor (9) in einem Zellbad (6) angeordnet ist.
14. Apparatur nach Anspruch 13, wobei der Elektrolyt, der Puffer und das Zellbad aus demselben Medium mit dem einzigen Unterschied, dass der Elektrolyt und der Puffer, aber nicht das Zellbad, mit einem Agonisten supplementiert sind, bestehen.
15. Apparatur nach einem der Ansprüche 10 bis 14, die außerdem eine zweite Kapillare (14) zur Abgabe eines Puffers, der keinen Agonisten enthält, umfasst,

wobei die zweite Kapillare (14) mit einem Superfusionssystem (16) verbunden ist, wobei die Apparatur auch Mittel (10) zum Schalten der Position der Kapillaren derart, dass der "patch-clamped"-Biosensor (9) alternativ vor dem Auslass der ersten Kapillare (1) oder vor dem Auslass der zweiten Kapillare (14) platziert ist, umfasst.

16. Apparatur nach einem der Ansprüche 10 bis 14, die außerdem ein Mittel (17) zum Superfusionieren des "patch-clamped"-Biosensors (9) mit einem Puffer, der keinen Agonisten enthält, umfasst.

17. Apparatur nach Anspruch 16, die außerdem Mittel zum Pulsieren des Stroms des Puffers, der aus dem Superfusionsmittel abgegeben wird, umfasst.

18. Verfahren nach Anspruch 17, wobei das Mittel (17) eine Mikropipette ist.

19. Apparatur nach einem der Ansprüche 10 bis 18, wobei der Biosensor (9) aus wenigstens einer Zelle oder einem Teil einer Zelle besteht, die/der Rezeptoren für den zu detektierenden Modulator umfasst.

#### Revendications

1. Procédé de détection d'un modulateur de récepteur, **caractérisé en ce qu'il** comprend les étapes suivantes :

(I) un échantillon contenant le modulateur de récepteur est fractionné en utilisant des moyens d'électrophorèse capillaire,

(II) une fraction contenant le modulateur de récepteur est alimentée directement à un capteur biologique étudié par patch-clamp (9) qui est activé par un agoniste du récepteur et, en résultat de cette activation, génère une réponse mesurable, ledit agoniste étant alimenté au capteur biologique par les moyens d'électrophorèse capillaire conjointement avec le modulateur, ladite activation du capteur biologique (9) étant pulsée par la délivrance de l'agoniste du récepteur au capteur biologique pendant de courtes périodes de temps, lesdites périodes étant séparées par d'autres périodes pendant lesquelles pas d'agoniste n'est délivré au capteur biologique, et

(III) le changement de la réponse résultant de la désactivation du capteur biologique (9) activé par l'agoniste du récepteur par le modulateur du récepteur est mesuré.




2. Procédé selon la revendication 1, dans lequel la réponse générée par le capteur biologique (9) est mesurée durant les périodes pendant lesquelles pas

d'agoniste n'est délivré au capteur biologique.

3. Procédé selon la revendication 1 ou 2, dans lequel le capteur biologique désensibilisé est resensibilisé par la superfusion du capteur biologique par la délivrance de tampon pour le rinçage du capteur biologique. 5
4. Procédé selon la revendication 3, dans lequel la superfusion est réalisée en utilisant une colonne, placée parallèlement aux moyens d'électrophorèse capillaire. 10
5. Procédé selon la revendication 3, dans lequel la superfusion est réalisée en utilisant une pipette en verre placée avec son orifice de sortie adjacent à l'orifice de sortie des moyens d'électrophorèse capillaire. 15
6. Procédé selon l'une quelconque des revendications 1 à 5, dans lequel la réponse générée par le capteur biologique (9) est un courant électrique. 20
7. Procédé selon l'une quelconque des revendications 1 à 5, dans lequel la réponse générée par le capteur biologique (9) est la fluorescence. 25
8. Procédé selon l'une quelconque des revendications 1 à 7, dans lequel le capteur biologique (9) est constitué par au moins une cellule ou une partie d'une cellule comprenant au moins un récepteur pour l'agoniste utilisé et pour le modulateur à détecter. 30
9. Procédé selon l'une quelconque des revendications 1 à 8, dans lequel le modulateur à détecter est une substance affectant les canaux ioniques activés par des ligands. 35
10. Appareil de détection d'un modulateur de récepteur comprenant un capillaire de séparation d'électrophorèse capillaire (1) contenant un électrolyte supplémenté d'un agoniste de récepteur, dont la partie d'orifice d'entrée d'échantillon est connectée à une source d'énergie haute tension (2) par un flacon de tampon (3) contenant un tampon supplémenté d'un agoniste du récepteur et la partie d'orifice de sortie reliée à la terre (4) dont les extrémités sont proches d'un capteur biologique (9) étudié par patch-clamp qui est activé par l'agoniste du récepteur et désactivé par le modulateur fractionné ; l'appareil comprenant en outre une électrode de patch-clamp (8) et des moyens destinés à enregistrer les courants détectés par l'électrode de patch-clamp et des moyens destinés à la délivrance pulsée de l'agoniste du récepteur au capteur biologique. 50
11. Appareil selon la revendication 10, dans lequel le capillaire d'électrophorèse capillaire (1) est un ca-

pillaire en silice fondue.

12. Appareil selon la revendication 10 ou 11, comprenant en outre au moins un micropositionneur (10) connecté au capillaire et/ou à l'électrode de patch-clamp. 5
13. Appareil selon l'une quelconque des revendications 10 à 12, dans lequel le capteur biologique étudié par patch-clamp (9) est placé dans un bain cellulaire (6). 10
14. Appareil selon la revendication 13, dans lequel l'électrolyte, le tampon et le bain cellulaire sont constitués du même milieu, l'unique différence étant que l'électrolyte et le tampon mais pas le bain cellulaire sont supplémentés d'un agoniste. 15
15. Appareil selon l'une quelconque des revendications 10 à 14, comprenant en outre un second capillaire (14) destiné à la délivrance d'un tampon ne comprenant pas d'agoniste, ledit second capillaire (14) étant connecté à un système de superfusion (16), ledit appareil comprenant également des moyens (10) pour changer la position des capillaires de sorte que le capteur biologique étudié par patch-clamp (9) soit en variante placé en face de l'orifice de sortie du premier capillaire (1) et en face de l'orifice de sortie du second capillaire (14). 30
16. Appareil selon l'une quelconque des revendications 10 à 14, comprenant en outre des moyens (17) de superfusion du capteur biologique (9) étudié par patch-clamp avec un tampon ne comprenant pas d'agoniste. 35
17. Appareil selon la revendication 16, comprenant en outre des moyens destinés à pulser le flux du tampon délivré par les moyens de superfusion. 40
18. Procédé selon la revendication 17, dans lequel lesdits moyens (17) sont une micropipette. 45
19. Appareil selon l'une quelconque des revendications 10 à 18, dans lequel le capteur biologique (9) est constitué par au moins une cellule ou une partie d'une cellule comprenant des récepteurs pour le modulateur à détecter. 55

A. Absorbance Detection*Fig. 1A*B. Patch-Clamp Detector*Fig. 1B*C. Interlocked Pulsed Patch Clamp Detector*Fig. 1C*




Fig. 2






Fig. 3A






Fig. 3B






NO RESPONSE


Fig. 5A

○ = Analyte




RESPONSE


Fig. 5B



*Fig. 6A*



*Fig. 6B*



Time (sec)

*Fig. 6C*





Fig. 7

*Fig. 8*